Inhalation product development – expert capabilities and resources

Skyepharma has an established track record of successful development of inhalation products from initial concept to commercial manufacture and supply. This reputation was further strengthened by the approval in 2012 of flutiform® in Europe and its subsequent launch in a number of European countries, and its approval and launch in Japan in 2013. Skyepharma has also developed a number of other Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) products that have achieved approvals in over 30 countries worldwide including the US and Europe.

> Find out more 

Oral drug delivery – 30 years of experience

Skyepharma has 30 years of experience in oral modified release and has an enviable reputation for developing novel formulations of high-value drugs. Our expertise extends from formulation to process development and scale-up, and from technology transfer and regulatory affairs to commercial manufacture. We combine our breadth and depth of expertise with our range of technologies to control when and how orally administered drugs are best released in the body for optimal treatment. Oral products using Skyepharma technologies have achieved in-market sales of approximately US$4bn over the last 5 years.

> Find out more

Pmdi Aerosol Testing